flow trial semaglutide kidney outcomes 2024 nejm hazard ratio in patients with overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical ADA 24: FLOW Trial: Kidney

PET-CT scans combine two powerful imaging tools, giving doctors a detailed picture of whats happening in the body

Every study on the current topic utilized the FDA FAERS database for analyses 32,33,34

Weight regain and cardiometabolic effects after withdrawal of semaglutide

BPC-157 is not approved for human use by the MHRA in the UK or the FDA in the US

Your follicles aren't dead

Why this matters for India: Generic entry could unlock a 5,000+ crore opportunity over the next 1215 months Prices may drop 3050% initially, and potentially 7075% over time #GLP-1 adoption in diabetes care is expected to rise sharply, adding 0.51% to IPM growth in FY27 Competition is intensifying, with 1015 players vying for share across India, regulated, and emerging markets Novo Nordisk has already launched Ozempic in India (Dec 2025), setting the stage for one of the most closely watched generic transitions in recent pharma history